No results for ‘’
Aurobindo Pharma Ltd
₹1497.80
(3.75%)
Sun, 21 Jun 2026, 01:24 am
Health Technology
Pharmaceuticals: Other
24.5KAurobindo Pharma Debt to Equity Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 54.53 | 22.44 | 8.25 | 23.95 | 10.80 | 10.93 | 0 | 14.46 | 12.70 | 22.60 | 21.49 | 17.17 | 13.47 | 19.48 | 8.51 | 9.68 | 14.80 | 15.75 | 20.12 | 19.39 |
| Price to book ratio | 4.46 | 4.09 | 1.39 | 0.82 | 2.92 | 2.33 | 1.48 | 1.63 | 3.97 | 6.91 | 5.98 | 4.22 | 2.80 | 3.32 | 1.44 | 2.36 | 1.59 | 1.13 | 2.14 | 2.06 |
| Price to sales ratio | 2.42 | 2.13 | 0.81 | 0.40 | 1.72 | 1.45 | 0.76 | 0.74 | 1.86 | 2.96 | 3.22 | 2.69 | 2.01 | 2.39 | 1.06 | 2.10 | 1.67 | 1.23 | 2.22 | 2.15 |
| Price to cash flow ratio | 0 | 0 | 13.90 | 16.15 | 16.15 | 20.81 | 13.51 | 25.82 | 26.78 | 30.21 | 32.33 | 12.21 | 17.11 | 30.77 | 5.66 | 15.65 | 7.80 | 12.53 | 25.90 | 17.55 |
| Enterprise value | 4979Cr | 6012Cr | 3542Cr | 3445Cr | 8156Cr | 7906Cr | 6407Cr | 7425Cr | 18512Cr | 39592Cr | 47773Cr | 42355Cr | 36161Cr | 51066Cr | 27298Cr | 51356Cr | 37905Cr | 29415Cr | 64162Cr | 67616Cr |
| Enterprise value to EBITDA ratio | 31.86 | 21.18 | 11.15 | 6.34 | 10.59 | 8.54 | 11.92 | 8.89 | 8.92 | 15.77 | 16.06 | 13.11 | 10.10 | 13.82 | 5.61 | 9.47 | 8.51 | 7.70 | 11.23 | 10.49 |
| Debt to equity ratio | 1.69 | 2.35 | 1.65 | 1.89 | 1.18 | 0.74 | 1.29 | 1.29 | 1.01 | 0.86 | 0.69 | 0.36 | 0.41 | 0.50 | 0.35 | 0.24 | 0.13 | 0.20 | 0.22 | 0.25 |
| Return on equity % | 9.34 | 23.63 | 23.73 | 4.34 | 36.56 | 26.85 | -5.16 | 11.88 | 36.91 | 35.39 | 32.55 | 27.63 | 23.02 | 18.50 | 18.53 | 27.54 | 11.39 | 7.50 | 11.20 | 11.16 |
Aurobindo Pharma Ltd Debt to Equity Ratio
The Aurobindo Pharma Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Aurobindo Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Aurobindo Pharma Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Aurobindo Pharma Ltd (NSE: AUROPHARMA, BSE: 524804) is currently trading at ₹1497.80, with a market capitalization of ₹83812.58Cr. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Aurobindo Pharma Ltd Debt to Equity Ratio is essential for fundamental analysis.
Aurobindo Pharma Ltd Debt to Equity Ratio Current Value
The current Aurobindo Pharma Ltd Debt to Equity Ratio stands at 0.25.
The latest Aurobindo Pharma Ltd Debt to Equity Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Aurobindo Pharma Ltd Debt to Equity Ratio Historical Trend
The Aurobindo Pharma Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.25
- 2023: 0.22
- 2022: 0.20
- 2021: 0.13
- 2020: 0.24
The recent rise in Aurobindo Pharma Ltd Debt to Equity Ratio suggests strengthening valuation trends and improving market sentiment.
What Aurobindo Pharma Ltd Debt to Equity Ratio Indicates for Investors
The Aurobindo Pharma Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Aurobindo Pharma Ltd Debt to Equity Ratio Analysis Summary
The Aurobindo Pharma Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Aurobindo Pharma Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Aurobindo Pharma Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.